Novartis' drug ianalumab meets Phase III endpoints in Sjögren's disease trials, potentially offering the first targeted therapy for this chronic autoimmune disorder.
US DOJ seeks to revoke antitrust immunity for Delta-Aeroméxico joint venture, as antitrust enforcement intensifies across sectors.
Novartis' drug ianalumab meets Phase III endpoints in Sjögren's disease trials, potentially offering the first targeted therapy for this chronic autoimmune disorder.
US DOJ seeks to revoke antitrust immunity for Delta-Aeroméxico joint venture, as antitrust enforcement intensifies across sectors.